D
Debbie-Ann N. Nathan
Researcher at National Institutes of Health
Publications - 4
Citations - 1408
Debbie-Ann N. Nathan is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Antigen & CD28. The author has an hindex of 4, co-authored 4 publications receiving 1258 citations.
Papers
More filters
Journal ArticleDOI
Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
James N. Kochenderfer,Mark E. Dudley,Sadik H. Kassim,Robert Somerville,Robert O. Carpenter,Maryalice Stetler-Stevenson,James Chih-Hsin Yang,Giao Q. Phan,Michael S. Hughes,Richard M. Sherry,Mark Raffeld,Steven R. Feldman,Lily Lu,Yong F. Li,Lien T. Ngo,Andre Goy,Tatyana Feldman,David Spaner,Michael L. Wang,Clara C. Chen,Sarah M. Kranick,Avindra Nath,Debbie-Ann N. Nathan,Kathleen E. Morton,Mary Ann Toomey,Steven A. Rosenberg +25 more
TL;DR: The results demonstrate the feasibility and effectiveness of treating chemotherapy-refractory B-cell malignancies with anti-CD19 CAR T cells and provide strong support for further development of this approach.
Journal ArticleDOI
A Phase I Clinical Trial of Treatment of B-Cell Malignancies with Autologous Anti-CD19-CAR-Transduced T Cells
James N. Kochenderfer,Mark E. Dudley,Maryalice Stetler-Stevenson,Wyndham H. Wilson,John E. Janik,Debbie-Ann N. Nathan,Irina Maric,Mark Raffeld,Steven A. Feldman,Richard A. Morgan,Steven A. Rosenberg +10 more
TL;DR: Adoptive transfer of autologous T cells expressing anti-CD19 CARs is an attractive new approach for treating B-cell malignancies after treatment with chemotherapy, and CAR-transduced T cells were widely distributed with the highest levels in the spleen and bone marrow.
Journal ArticleDOI
Effective Treatment Of Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma With Autologous T Cells Genetically-Engineered To Express An Anti-CD19 Chimeric Antigen Receptor
Mark E. Dudley,Sadik H. Kassim,Robert O. Carpenter,James Chih-Hsin Yang,Giao Q. Phan,Michael S. Hughes,Richard M. Sherry,Steven R. Feldman,David Spaner,Debbie-Ann N. Nathan,Kathleen E. Morton,Mary Ann Toomey,Steven A. Rosenberg +12 more
TL;DR: The results demonstrate the feasibility of treating patients with chemotherapy-refractory B-cell malignancies by using autologous anti-CD19 CAR T cells and the numerous remissions obtained should encourage further development of this approach.
Journal ArticleDOI
B-Cell Depletion, Remissions of Malignancy, and Cytokine-Associated Toxicity in a Clinical Trial of T Cells Genetically-Engineered to Express An Anti-CD19 Chimeric Antigen Receptor
James N. Kochenderfer,Mark E. Dudley,Steven R. Feldman,Wyndham H. Wilson,David Spaner,Laura Devillier,Robert J. Carpenter,Debbie-Ann N. Nathan,Irina Maric,Richard A. Morgan,Steven A. Rosenberg +10 more
TL;DR: Patients on this clinical trial received infusions of autologous T cells that are transduced with gamma-retroviruses encoding an anti-CD19 CAR, and a striking depletion of CD19 + B-lineage cells occurred, which lasted for up to 15 months, and it is ongoing in 3 of 4 patients.